Cancer Prevention Pharmaceuticals

Cancer Prevention Pharmaceuticals, founded in 2008 in Tucson, Arizona, develops eflornithine (DFMO), an ornithine decarboxylase inhibitor, for cancer prevention. Its phase 3 trials combined eflornithine with sulindac in familial adenomatous polyposis and in patients with a history of colorectal adenomas, registered on ClinicalTrials.gov under the company as lead sponsor; the combination did not reach approval, though eflornithine itself was later approved by another company for neuroblastoma maintenance.